TransMedics Group (TMDX) investor relations material

Strategic Achievements and Business Model

• Achieved 86% compound annual growth rate since FY22, with a $140M swing to profitability and multi-organ platform expansion, including three FDA-approved products and one in development.

• Developed advanced organ preservation technology, enabling superior clinical outcomes and higher organ utilization.

• Built a national end-to-end service model (NOP) and vertically integrated logistics, including air and ground transport, with 20 clinical hubs, 22 transplant aircraft, over 140 pilots, 50+ procurement surgeons, and 250+ clinical specialists.

• Established a secure digital ecosystem for transplant program management, real-time coordination, and added donor/recipient screening services.

• Managed over 35% of national transplant volume through its digital command center last year.

Growth Initiatives and Expansion Plans

• Four growth drivers: expanding heart and lung adoption, launching OCS Kidney, EU expansion, and developing next-gen OCS 3.0 platform.

• Targeting expansion in heart and lung markets with new technologies (OCS and CHOPS), aiming to access 5,400 additional transplants annually, supported by ENHANCE Heart and DENOVO Lung studies.

• OCS Kidney program targets the largest transplant segment, aiming to reduce discards and complications, addressing a $10.3B annual cost burden, with rollout in the second half of 2027.

• Replicating the U.S. service model in Europe to nearly double the addressable market, leveraging PAD Aviation for logistics and comparable donor and center footprint.

• Launching OCS 3.0 platform with cloud connectivity, automation, and supply-chain independence, with phased rollouts through 2032.

Financial Performance and Outlook

• Revenue grew from $94M in FY22 to a projected $605M in FY25, with profitability achieved in FY24 and expanding margins in FY25.

• FY26 revenue guidance is $737–$757M, representing 22–25% YoY growth; cash and equivalents stood at $472.7M as of June 30, 2026.

• Achieved 86% revenue growth over four years, with a healthy balance sheet and 20%-25% growth guidance for the current year.

• Q2 saw 15% product revenue growth and 30% service revenue growth, with normalization expected as logistics contracts annualize.

• Product revenue growth in Q2 was seen as an anomaly, with expectations for healthy growth to meet annual guidance.